Mainz Biomed N.V. (MYNZ)
NASDAQ (CM) NASDAQ (CM) Primary Summary
MYNZ Chart
2 Small-Cap Biotechs That Could Reward Patient Investors
Speculative investors and patience rarely go hand in hand. Nevertheless, if you're looking to invest in the small-cap biotech sector, patience is a requirement.
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
Mainz Biomed N.V. MYNZ announced a 1-for-40 reverse stock split, effective Dec. 3.
Mainz Biomed N.V. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| RS Richard Slavik Newbridge Financial Services Group Inc. | 500 | $2.16 | - | -$2.16 | -100% |
 Provenance Wealth Advisors LLC Provenance Wealth Advisors LLC | 1,171 | $3,759 | $3,758.91 | -$0.09 | - |
Mainz Biomed N.V. (MYNZ) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Mainz Biomed N.V. Profile
| Professional Services Industry | Industrials Sector | Guido Baechler CEO | NASDAQ (CM) Exchange | N5436L101 CUSIP |
| DE Country | 19 Employees | - Last Dividend | 3 Dec 2024 Last Split | 5 Nov 2021 IPO Date |
Overview
Mainz Biomed N.V. is a pioneering molecular genetics cancer diagnostic company engaged in the development of in-vitro diagnostic (IVD) tests and research use only (RUO) assays aimed at clinical diagnostics. Founded in 2008 and headquartered in Mainz, Germany, the company is at the forefront of creating innovative solutions for cancer screening. Its collaborative efforts with Microba Life Sciences for the discovery and development of novel therapeutics highlight its commitment to combating major diseases through leading-edge research.
Products and Services
- ColoAlert - This flagship product is a stool-based deoxyribonucleic acid (DNA) test designed for colorectal cancer screening. It offers a non-invasive, easy-to-use option for early detection of colorectal cancer, significantly improving the chances of successful treatment and survival rates.
- PancAlert - Currently a product candidate, PancAlert represents Mainz Biomed's initiative to expand its cancer screening portfolio to include pancreatic cancer. This test aims to facilitate early detection of one of the most challenging forms of cancer, potentially saving lives through earlier intervention.
